Abstract: The invention relates to novel crystal forms of azithromycin, an antibiotic useful in the treatment of infections.

Abstract: The invention provides methods of treating infection, such as Chlamydia pneumoniae infection, in a mammal comprising administering to a mammal effective amounts of azithromycin and a glycogen phosphorylase inhibitor. The invention also provides methods of treating atherosclerosis by administration of effective amounts of azithromycin and a glycogen phosphorylase inhibitor. Pharmaceutical compositions and kits are also provided.

Abstract: The present invention relates to the soakable crystal structures of a phosphodiesterase 5 (PDE5) and their uses in identifying PDE5 ligands, including PDE5 inhibitor compounds. The present invention also relates to methods of identifying such PDE5 inhibitor compounds and their medical use. The present invention additionally relates to crystals of PDE5 into which ligands may be soaked and crystals of PDE5 comprising PDE5 ligands that have been soaked into the crystal.

Abstract: A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal comprising administration of a GABAA inverse agonist or a pharmaceutically acceptable salt thereof; and a nicotine receptor partial agonist, an estrogenic agent, selective estrogen receptor modulator or vitamin E or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

Abstract: A corticotropin releasing factor (CRF) antagonist is administered to treat a condition selected from the group consisting of:

Abstract: The invention describes novel PAR polypeptides and uses thereof. It relates in particular to PAR polypeptides lacking their functional endogenous activating peptide and capable of interacting constitutively with a ligand for a wild-type PAR. The invention also lies in methods of screening for active compounds, using modified PAR polypeptides, and also in the therapeutic use of identified compounds, in particular for the treatment of inflammation, of allergies, of diseases affecting the CNS, of neurodegeneration, or of psychiatric or cardiovascular diseases, and also in methods and compositions which can be used for this purpose. Other subjects of the invention include nucleic acids encoding a modified PAR, vectors and recombinant host cells and transgenic animals containing them, and also their uses in the context of a therapeutic, diagnostic or screening approach, for example.

Abstract: A process for preparing a compound of the formula useful as a non-steroidal glucocorticoid receptor modulator.

Abstract: The present invention provides an essentially nonaqueous, liquid pharmaceutical concentrate composition for oral administration containing sertraline or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The present invention also provides a use of this concentrate composition to prepare an aqueous solution of sertraline. In addition, the present invention provides a method of using this concentrate composition to treat or prevent a variety of diseases or conditions. Finally, the present invention provides the compound, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine methanesulfonate.

Abstract: This invention relates to methods of preparing a compound of Formulae 2, 5 and 7, wherein R2-R5, R7, R9, R10 and R15 are defined herein.

Abstract: This invention provides a compound of the formula: or its pharmaceutically acceptable salt thereof, wherein A is partially unsaturated or unsaturated five membered heterocyclic, or partially unsaturated or unsaturated five membered carbocyclic, wherein the 4-(sulfonyl)phenyl and the 4-substituted phenyl in the formula (I) are attached to ring atoms of Ring A, which are adjacent to each other; R1 is optionally substituted aryl or heteroaryl, with the proviso that when A is pyrazole, R1 is heteroaryl; R2 is C1-4 alkyl, halo-substituted C1-4 alkyl, C1-4 alkylamino, C1-4 dialkylamino or amino; R3, R4 and R5 are independently hydrogen, halo,, C1-4 alkyl, halo-substituted C1-4 alkyl or the like; or two of R3, R4 and R5 are taken together with atoms to which they are attached and form a 4-7 membered ring; R6 and R7 are independently hydrogen, halo, C1-4 alkyl, halo-substituted C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylamino or N,N-di C1-4 alkylamino; and m and n are independently 1, 2, 3 o

Abstract: The invention provides compounds of formula VI 1

Abstract: The present invention provides processes useful in the preparation of certain &bgr;3-adrenergic receptor agonists of the structural formula 1

Abstract: Combinations comprising a) an inhibitor of cyclic guanosine monophosphate (cGMP) specific phosphodiesterase type 5 (PDE5) inhibitor and b) an inhibitor of angiotensin converting enzyme (ACE) are useful for treating hypertension.

Abstract: The present invention relates to compounds of the formula: 1

Abstract: The invention provides controlled release pharmaceutical formulations having a coated core with the core comprising a drug-containing composition and a water-swellable composition, each occupying essentially separate regions within the core. The drug-containing composition comprises a PDE4D inhibitor, or a pharmaceutically acceptable salt thereof, preferably (R)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid, or a pharmaceutically acceptable salt thereof, or 2-(4-fluorophenoxy)-N-[4-(1-hydroxy-1-methyl-ethyl)-benzyl]-nicotinamide, or a pharmaceutically acceptable salt thereof, and a drug-entraining agent. The coating around the core is water-permeable, water-insoluble, and has at least one delivery port therethrough.

Abstract: This invention provides a method for initiation of farrowing of pregnant domestic swine within a predictable number of hours by administering a progesterone receptor antagonist. The present method also significantly reduces reduce stillborn pigs. A preferred progesterone receptor antagonist for use in the present method is RU38,486. The progesterone receptor antagonist can be administered to a pregnant swine via an appropriate route of administration, such as orally, intramuscularly or intravaginally. The present invention greatly facilitates human supervision and assistance during parturition, and is important for the production and profitability of farrowing operation.

Abstract: A laboratory fume hood utilities manifold for the distribution of a plurality of utilities has an elongated housing frame with the separate intake ports for different respective utilities, such as air, vacuum, nitrogen and water. The manifold includes a plurality of conduits wherein each conduit communicates with a respective intake port. A plurality of outlet ports is connected to each respective conduit. Each outlet port is facing the front of the hood and may selectively be provided with a valve for the controlled supply of the utilities. The manifold also includes a drain outlet port for condenser cooling water disposal, wherein the drain outlet port is disposed below the intake ports, and a drain intake port and downwardly angled drain conduit communicates by gravity flow with the drain outlet port. A downwardly angled steel tube is connected to the drain outlet with the steel tube free end disposed in the fume hood drain.

Abstract: The present invention relates to novel alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines, to intermediates and methods for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

Abstract: Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the modulation of the cannabinoid receptors in animals are described herein.

Abstract: A compound of the formula wherein W, R1, R2, R3, R4, R5, R6, R7, R8 and R13 are as defined herein, useful in the treatment of obesity, overweight condition, hyperlipidemia, glaucoma, cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism, thyroid cancer and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, congestive heart failure, hypercholesteremia, depression, osteoporosis and hair loss.